Search

Your search keyword '"Hackert, T"' showing total 1,378 results
Start Over Author "Hackert, T"
1,378 results on '"Hackert, T"'

8. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma

Author

Giaccherini, M, primary, Rende, M, additional, Gentiluomo, M, additional, Corradi, C, additional, Archibugi, L, additional, Ermini, S, additional, Maiello, E, additional, Morelli, L, additional, van Eijck, C H J, additional, Cavestro, G M, additional, Schneider, M, additional, Mickevicius, A, additional, Adamonis, K, additional, Basso, D, additional, Hlavac, V, additional, Gioffreda, D, additional, Talar-Wojnarowska, R, additional, Schöttker, B, additional, Lovecek, M, additional, Vanella, G, additional, Gazouli, M, additional, Uno, M, additional, Malecka-Wojciesko, E, additional, Vodicka, P, additional, Goetz, M, additional, Bijlsma, M F, additional, Petrone, M C, additional, Bazzocchi, F, additional, Kiudelis, M, additional, Szentesi, A, additional, Carrara, S, additional, Nappo, G, additional, Brenner, H, additional, Milanetto, A C, additional, Soucek, P, additional, Katzke, V, additional, Peduzzi, G, additional, Rizzato, C, additional, Pasquali, C, additional, Chen, X, additional, Capurso, G, additional, Hackert, T, additional, Bueno-de-Mesquita, B, additional, Uzunoglu, F G G, additional, Hegyi, P, additional, Greenhalf, W, additional, Theodoropoulos, G E E, additional, Sperti, C, additional, Perri, F, additional, Oliverius, M, additional, Mambrini, A, additional, Tavano, F, additional, Farinella, R, additional, Arcidiacono, P G, additional, Lucchesi, M, additional, Bunduc, S, additional, Kupcinskas, J, additional, Di Franco, G, additional, Stocker, S, additional, Neoptolemos, J P, additional, Bambi, F, additional, Jamroziak, K, additional, Testoni, S G G, additional, Aoki, M N, additional, Mohelnikova-Duchonova, B, additional, Izbicki, J R, additional, Pezzilli, R, additional, Lawlor, R T, additional, Kauffmann, E F, additional, López de Maturana, E, additional, Malats, N, additional, Canzian, F, additional, and Campa, D, additional

Published
2024
Full Text
View/download PDF

14. Natural history of the remnant duct after whipple for IPMN: results from an international consortium

Author

Kim, R.C., primary, Rocha Castellanos, D.M., additional, Kirsch, M.J., additional, Sacks, G.D., additional, Perinel, J., additional, Goh, B., additional, Heckler, M., additional, Hackert, T., additional, Adham, M., additional, Wolfgang, C., additional, Del-Chiaro, M., additional, Jang, J.Y., additional, Fernandez-Del Castillo, C., additional, Ceppa, E.P., additional, Salvia, R., additional, Schmidt, C.M., additional, Marchegiani, G., additional, and Roch, A.M., additional

Published
2024
Full Text
View/download PDF

15. Spectral characterization of intraoperative renal perfusion using hyperspectral imaging and artificial intelligence.

Author

Studier-Fischer, A., Bressan, M., Qasim, A.bin, Özdemir, B., Sellner, J., Seidlitz, S., Haney, C. M., Egen, L., Michel, M., Dietrich, M., Salg, G. A., Billmann, F., Nienhüser, H., Hackert, T., Müller, B. P., Maier-Hein, L., Nickel, F., and Kowalewski, K. F.

Subjects
ARTIFICIAL intelligence, PERFUSION, ISOLATION perfusion, KIDNEY surgery, SPECTRAL reflectance, HYPEREMIA, SPECTRAL imaging
Abstract

Accurate intraoperative assessment of organ perfusion is a pivotal determinant in preserving organ function e.g. during kidney surgery including partial nephrectomy or kidney transplantation. Hyperspectral imaging (HSI) has great potential to objectively describe and quantify this perfusion as opposed to conventional surrogate techniques such as ultrasound flowmeter, indocyanine green or the subjective eye of the surgeon. An established live porcine model under general anesthesia received median laparotomy and renal mobilization. Different scenarios that were measured using HSI were (1) complete, (2) gradual and (3) partial malperfusion. The differences in spectral reflectance as well as HSI oxygenation (StO2) between different perfusion states were compelling and as high as 56.9% with 70.3% (± 11.0%) for "physiological" vs. 13.4% (± 3.1%) for "venous congestion". A machine learning (ML) algorithm was able to distinguish between these perfusion states with a balanced prediction accuracy of 97.8%. Data from this porcine study including 1300 recordings across 57 individuals was compared to a human dataset of 104 recordings across 17 individuals suggesting clinical transferability. Therefore, HSI is a highly promising tool for intraoperative microvascular evaluation of perfusion states with great advantages over existing surrogate techniques. Clinical trials are required to prove patient benefit. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. IDEAL Stage I Klinische Studie Bestätigt Brauchbarkeit und Sicherheit der Visualisierung von Pankreasleckagen mit SmartPAN Indikator

Author

El-Mahdy, J., additional, Holze, M., additional, Rossion, I., additional, Wagner, M., additional, Sander, A., additional, Tenckhoff, S., additional, Sundermann, T., additional, Probst, P., additional, Larmann, J., additional, Pianka, F., additional, Hackert, T., additional, Klotz, R., additional, and Pausch, T., additional

Published
2023
Full Text
View/download PDF

26. Development of biotissue training models for anastomotic suturing in pancreatic surgery

Author

Karadza, E., primary, Haney, C.M., additional, Limen, E.F., additional, Müller, P.C., additional, Kowalewski, K.F., additional, Sandini, M., additional, Wennberg, E., additional, Schmidt, M.W., additional, Felinska, E.A., additional, Lang, F., additional, Salg, G., additional, Kenngott, H.G., additional, Rangelova, E., additional, Mieog, S., additional, Vissers, F., additional, Korrel, M., additional, Zwart, M., additional, Sauvanet, A., additional, Loos, M., additional, Mehrabi, A., additional, de Santibanes, M., additional, Shrikhande, S.V., additional, Abu Hilal, M., additional, Besselink, M.G., additional, Müller-Stich, B.P., additional, Hackert, T., additional, and Nickel, F., additional

Published
2023
Full Text
View/download PDF

28. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial

Author

Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., Sripadam, R., Mukherjee, S., Soonawalla, Z., Wadsley, J., Al-Mukhtar, A., Dickson, E., Graham, J., Jiao, L., Wasan, H. S., Tait, I. S., Prachalias, A., Ross, P., Valle, J. W., O'Reilly, D. A., Al-Sarireh, B., Gwynne, S., Ahmed, I., Connolly, K., Yim, K. L., Cunningham, D., Armstrong, T., Archer, C., Roberts, K., Ma, Y. T., Springfeld, C., Tjaden, C., Hackert, T., Büchler, M. W., Neoptolemos, J. P., and European Study Group for Pancreatic Cancer

Subjects
Hepatology, Gastroenterology
Abstract

BACKGROUND: Patients with borderline resectable pancreatic ductal adenocarcinoma have relatively low resection rates and poor survival despite the use of adjuvant chemotherapy. The aim of our study was to establish the feasibility and efficacy of three different types of short-course neoadjuvant therapy compared with immediate surgery. METHODS: ESPAC5 (formerly known as ESPAC-5f) was a multicentre, open label, randomised controlled trial done in 16 pancreatic centres in two countries (UK and Germany). Eligible patients were aged 18 years or older, with a WHO performance status of 0 or 1, biopsy proven pancreatic ductal adenocarcinoma in the pancreatic head, and were staged as having a borderline resectable tumour by contrast-enhanced CT criteria following central review. Participants were randomly assigned by means of minimisation to one of four groups: immediate surgery; neoadjuvant gemcitabine and capecitabine (gemcitabine 1000 mg/m(2) on days 1, 8, and 15, and oral capecitabine 830 mg/m(2) twice a day on days 1-21 of a 28-day cycle for two cycles); neoadjuvant FOLFIRINOX (oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), folinic acid given according to local practice, and fluorouracil 400 mg/m(2) bolus injection on days 1 and 15 followed by 2400 mg/m(2) 46 h intravenous infusion given on days 1 and 15, repeated every 2 weeks for four cycles); or neoadjuvant capecitabine-based chemoradiation (total dose 50.4 Gy in 28 daily fractions over 5.5 weeks [1.8 Gy per fraction, Monday to Friday] with capecitabine 830 mg/m(2) twice daily [Monday to Friday] throughout radiotherapy). Patients underwent restaging contrast-enhanced CT at 4-6 weeks after neoadjuvant therapy and underwent surgical exploration if the tumour was still at least borderline resectable. All patients who had their tumour resected received adjuvant therapy at the oncologist's discretion. Primary endpoints were recruitment rate and resection rate. Analyses were done on an intention-to-treat basis. This trial is registered with ISRCTN, 89500674, and is complete. FINDINGS: Between Sept 3, 2014, and Dec 20, 2018, from 478 patients screened, 90 were randomly assigned to a group (33 to immediate surgery, 20 to gemcitabine plus capecitabine, 20 to FOLFIRINOX, and 17 to capecitabine-based chemoradiation); four patients were excluded from the intention-to-treat analysis (one in the capecitabine-based chemoradiotherapy withdrew consent before starting therapy and three [two in the immediate surgery group and one in the gemcitabine plus capecitabine group] were found to be ineligible after randomisation). 44 (80%) of 55 patients completed neoadjuvant therapy. The recruitment rate was 25.92 patients per year from 16 sites; 21 (68%) of 31 patients in the immediate surgery and 30 (55%) of 55 patients in the combined neoadjuvant therapy groups underwent resection (p=0.33). R0 resection was achieved in three (14%) of 21 patients in the immediate surgery group and seven (23%) of 30 in the neoadjuvant therapy groups combined (p=0.49). Surgical complications were observed in 29 (43%) of 68 patients who underwent surgery; no patients died within 30 days. 46 (84%) of 55 patients receiving neoadjuvant therapy were available for restaging. Six (13%) of 46 had a partial response. Median follow-up time was 12.2 months (95% CI 12.0-12.4). 1-year overall survival was 39% (95% CI 24-61) for immediate surgery, 78% (60-100) for gemcitabine plus capecitabine, 84% (70-100) for FOLFIRINOX, and 60% (37-97) for capecitabine-based chemoradiotherapy (p=0.0028). 1-year disease-free survival from surgery was 33% (95% CI 19-58) for immediate surgery and 59% (46-74) for the combined neoadjuvant therapies (hazard ratio 0.53 [95% CI 0.28-0.98], p=0.016). Three patients reported local disease recurrence (two in the immediate surgery group and one in the FOLFIRINOX group). 78 (91%) patients were included in the safety set and assessed for toxicity events. 19 (24%) of 78 patients reported a grade 3 or worse adverse event (two [7%] of 28 patients in the immediate surgery group and 17 [34%] of 50 patients in the neoadjuvant therapy groups combined), the most common of which were neutropenia, infection, and hyperglycaemia. INTERPRETATION: Recruitment was challenging. There was no significant difference in resection rates between patients who underwent immediate surgery and those who underwent neoadjuvant therapy. Short-course (8 week) neoadjuvant therapy had a significant survival benefit compared with immediate surgery. Neoadjuvant chemotherapy with either gemcitabine plus capecitabine or FOLFIRINOX had the best survival compared with immediate surgery. These findings support the use of short-course neoadjuvant chemotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. FUNDING: Cancer Research UK.

Published
2023

29. Morbus Crohn

Author

Tjaden, C., Hackert, T., Schmidt, J., Siewert, Jörg Rüdiger, editor, Rothmund, Matthias, editor, and Schumpelick, Volker, editor

Published
2011
Full Text
View/download PDF

30. Prediction Model for Severe Morbidity and Diabetes Type III after Central Pancreatectomy: Patient Selection in an International Retrospective Multicenter Study

Author

van Bodegraven, E.A., primary, Lof, S., additional, Jones, L., additional, Aussilhou, B., additional, Yong, G., additional, Jishu, W., additional, Klotz, R., additional, Rocha-Castellanos, D.M., additional, Matsumato, I., additional, de Ponthaud, C., additional, Tanaka, K., additional, Biesel, E., additional, Kauffmann, E., additional, Dumitrascu, T., additional, Nagakawa, Y., additional, Martí-Cruchaga, P., additional, Roeyen, G., additional, Zerbi, A., additional, Goetz, M., additional, de Meijer, V., additional, Pessaux, P., additional, Ignatavicius, P., additional, Demir, I., additional, Giuffrida, M., additional, Tingstedt, B., additional, Marino, M.V., additional, Mastoridis, S., additional, Brunner, M., additional, Mora-Oliver, I., additional, Bortolato, C., additional, Gulla, A., additional, Apers, T., additional, Hermand, H., additional, Mitsuka, Y., additional, Popescu, I., additional, Boggi, U., additional, Wittel, U., additional, Hirano, S., additional, Gaujoux, S., additional, Kamei, K., additional, Fernández-Del Castillo, C., additional, Hackert, T., additional, Kuirong, J., additional, Yi, M., additional, and Sauvanet, A., additional

Published
2023
Full Text
View/download PDF

32. Polymorphic variants involved in methylation regulation: a new strategy to discover risk loci for pancreatic ductal adenocarcinoma

Author

Corradi, Chiara, primary, Lencioni, G., additional, Gentiluomo, M., additional, Latiano, A., additional, Kiudelis, G., additional, van Eijck, C., additional, Marta, K., additional, Lawlor, R., additional, Tavano, F., additional, Boggi, U., additional, Dijk, F., additional, Cavestro, G., additional, Vermeulen, R., additional, Hackert, T., additional, Petrone, M., additional, Uzunoglu, F., additional, Archibugi, L., additional, Izbicki, J., additional, Mesquita, B. Bueno-de-, additional, Morelli, L., additional, Zerbi, A., additional, Stocker, H., additional, Talar-Wojnarowska, R., additional, Di Franco, G., additional, Hegyi, P., additional, Sperti, C., additional, Carrara, S., additional, Capurso, G., additional, Gazouli, M., additional, Brenner, H., additional, Bunduc, S., additional, Busch, O., additional, Landi, S., additional, Perri, F., additional, Oliverius, M., additional, Goetz, M., additional, Scognamiglio, P., additional, Mambrini, A., additional, Arcidiacono, P., additional, Kreivenaite, E., additional, Kupcinskas, J., additional, Hussein, T., additional, Ermini, S., additional, Milanetto, A., additional, Vodicka, P., additional, Kiudelis, V., additional, Hlavac, V., additional, Soucek, P., additional, Theodoropoulos, G., additional, Basso, D., additional, Aoki, M., additional, Pezzilli, R., additional, Pasquali, C., additional, Chammas, R., additional, Testoni, S., additional, Mohelníková-Duchoňová, B., additional, Lucchesi, M., additional, Neoptolemos, J., additional, Canzian, F., additional, and Campa, D., additional

Published
2022
Full Text
View/download PDF

33. Evaluation of the prognostic role of aspirin and metformin in the ESPAC 4 randomised trial of adjuvant gemcitabine versus gemcitabine plus capecitabine in patients with resected pancreatic cancer

Author

Ponweera, Arachchige, primary, Robinson, M., additional, Jackson, R., additional, Halloran, C., additional, Palmer, D., additional, Hackert, T., additional, Costello, E., additional, Greenhalf, W., additional, BÜchler, M., additional, Neoptolemos, J., additional, and Ghaneh, P., additional

Published
2022
Full Text
View/download PDF

34. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians

Author

Gentiluomo, Manuel, primary, Piccardi, M., additional, Bertoncini, S., additional, Costello, E., additional, Morelli, L., additional, Landi, S., additional, Milanetto, A., additional, Schöttker, B., additional, Di Franco, G., additional, Ermini, S., additional, Scarpa, A., additional, Izbicki, J., additional, Pezzilli, R., additional, Uzunoglu, F., additional, Talar-Wojnarowska, R., additional, Goetz, M., additional, Lawlor, R., additional, Aoki, M., additional, Bueno-de-Mesquita, B., additional, Busch, O., additional, Chammas, R., additional, Tavano, F., additional, van Laarhoven, H., additional, Cavestro, G., additional, Stocker, H., additional, Bazzocchi, F., additional, Pasquali, C., additional, Chen, X., additional, Puzzono, M., additional, Ponz de Leon Pisani, R., additional, Sperti, C., additional, Lovecek, M., additional, Erőss, B., additional, Basso, D., additional, Kupcinskas, J., additional, Vanagas, T., additional, Janciauskas, D., additional, Poskiene, L., additional, Tacelli, M., additional, Duchonova, B. Mohelnikova, additional, Perri, F., additional, Latiano, A., additional, Mambrini, A., additional, Maiello, E., additional, Hegyi, P., additional, Szentesi, A., additional, Bunduc, S., additional, Hussein, T., additional, Arcidiacono, P., additional, Boggi, U., additional, Hackert, T., additional, Soucek, P., additional, Lucchesi, M., additional, Ginocchi, L., additional, Gazouli, M., additional, Zerbi, A., additional, Roth, S., additional, Jamroziak, K., additional, Carrara, S., additional, Hlavac, V., additional, Oliverius, M., additional, Neoptolemos, J., additional, Theodoropoulos, G., additional, van Eijck, C., additional, Dannemann, M., additional, Canzian, F., additional, Tofanelli, S., additional, and Campa, D., additional

Published
2022
Full Text
View/download PDF

35. Polymorphisms in Transcription Factor Binding Sites and Enhancers as Pancreatic Ductal Adenocarcinoma Risk Factors

Author

Unal, Pelin, primary, Lu, Y., additional, Aoki, M., additional, Chammas, R., additional, Gazouli, M., additional, Theodoropoulos, G., additional, van Eijck, C., additional, Bijlsma, M., additional, Dijk, F., additional, Bueno-de-Mesquita, B., additional, Kupcinskas, J., additional, Kiudelis, V., additional, Kreivenaite, E., additional, Kondrackiene, J., additional, Malecka-Wojciesko, E., additional, Talar-Wojnarowska, R., additional, Kapszewicz, M., additional, Hegyi, P., additional, Szentesi, A., additional, Eross, B., additional, Bunduc, S., additional, Mohelnikova-Duchonova, B., additional, Soucek, P., additional, Hlavac, V., additional, Oliverius, M., additional, Vodickova, L., additional, Cervena, K., additional, Hackert, T., additional, Neoptolemos, J., additional, Goetz, M., additional, Uzunoglu, F., additional, Izbicki, J., additional, Stocker, H., additional, Schöttker, B., additional, Brenner, H., additional, Perri, F., additional, Tavano, F., additional, Palmieri, O., additional, Bazzocchi, F., additional, Maiello, E., additional, Testoni, S., additional, Petrone, M., additional, Arcidiacono, P., additional, Landi, S., additional, Ermini, S., additional, Bambi, F., additional, Boggi, U., additional, Capurso, G., additional, Archibugi, L., additional, Vanella, G., additional, Cavestro, G., additional, Morelli, L., additional, Di Franco, G., additional, Milanetto, A., additional, Sperti, C., additional, Pasquali, C., additional, Basso, D., additional, Pezzilli, R., additional, Lawlor, R., additional, Capretti, G., additional, Carrara, S., additional, Campa, D., additional, and Canzian, F., additional

Published
2022
Full Text
View/download PDF

39. Morbus Crohn

Author

Tjaden, C., Hackert, T., Schmidt, J., Schumpelick, Volker, editor, Siewert, Jörg Rüdiger, editor, and Rothmund, Matthias, editor

Published
2006
Full Text
View/download PDF

40. Chirurgie bei neuroendokrinen Neoplasien des Pankreas: State of the Art

Author

Nießen, A., Schimmack, S., Billmann, F., and Hackert, T.

Abstract

Pankreatische neuroendokrine Neoplasien (pNEN) werden mit zunehmender Inzidenz verzeichnet und vermehrt in frühen (resektablen) Stadien diagnostiziert. Aufgrund der Seltenheit dieser Neoplasien beruhen die Empfehlungen der verfügbaren Leitlinien vor allem auf retrospektiven Daten. Die onkologische und chirurgische Therapie dieser seltenen Erkrankung sollte spezialisierten Zentren vorbehalten sein. Bei resektablem Befund ohne Hinweis auf diffuse Filialisierung ist die kurativ intendierte vollständige Entfernung anzustreben. Alternativ zur chirurgischen Resektion wurde bei kleinen nichtfunktionellen Tumoren < 2 cm die Watch-and-wait-Strategie empfohlen, neuere Daten zeigen jedoch ein längeres Überleben nach Resektion von Neoplasien in der Größe zwischen 1 und 2 cm. Für benigne Insulinome und nichtfunktionelle gut differenzierte kleine pNEN stehen parenchymsparende Verfahren wie die Enukleation oder die Segmentresektion zur Verfügung. Die Frage des Einflusses von Lymphknotenmetastasen auf das langfristige tumorfreie und Gesamtüberleben und damit der Stellenwert der systematischen Lymphadenektomie ist nicht abschließend geklärt. Bei Neoplasien > 2 cm ist eine formelle Resektion mit Lymphadenektomie anzustreben. Minimal-invasive und robotisch assistierte Verfahren haben einen zunehmenden Stellenwert auch bei formellen Resektionen.

Published
2024
Full Text
View/download PDF

41. Stellenwert der Chirurgie bei fernmetastasierten neuroendokrinen Neoplasien des Pankreas

Author

Billmann, F., Nießen, A., and Hackert, T.

Abstract

Die Mehrzahl der Patienten mit pankreatischer neuroendokriner Neoplasie (pNEN) weist bereits bei Diagnosestellung eine Fernmetastasierung auf. Die Heterogenität der pNEN und das breite Spektrum der Therapiemöglichkeiten machen eine adäquate Patientenselektion und eine evidenzbasierte Strategie unerlässlich. Beim metastasierten pNEN konnte belegt werden, dass sowohl die Primariusresektion als auch die Resektion der Lebermetastasen zu einer Verbesserung des Gesamtüberlebens führen. Die chirurgische Behandlung der Lebermetastasen kann – insbesondere bei symptomatischen pNEN – auch in palliativer Absicht erfolgen und mit einem positiven Einfluss auf krankheitsfreies Überleben und Gesamtüberleben verbunden sein. Es stehen dem Chirurgen die klassischen Leberresektionstechniken sowie innovative Techniken (2-zeitige Resektionen, Lebertransplantation) zur Verfügung. Bei komplexem Befall gibt es zunehmende Evidenz für eine Kombination der Chirurgie mit ablativen Methoden. Eine Einbindung der Patienten in multimodale Konzepte ist aufgrund eines insgesamt hohen Rezidivrisikos nach Leberresektion immer erforderlich. Aktuelle Spannungsfelder in der Behandlung der metastasierten pNEN sind der Einsatz adjuvanter/neoadjuvanter Chemotherapie und der Chirurgie bei G3-NEN- und G3-NEC(neuroendokrines Karzinom)-Patienten. Ziel dieser Übersichtsarbeit ist es, den Stellenwert der Chirurgie bei fernmetastasierten NEN des Pankreas darzulegen.

Published
2024
Full Text
View/download PDF

44. Evidence Map of Pancreatic Surgery–A living systematic review with meta-analyses by the International Study Group of Pancreatic Surgery (ISGPS)

Author

Probst, P, Huttner, F, Meydan, O, Abu Hilal, M, Adham, M, Barreto, S, Besselink, M, Busch, O, Bockhorn, M, Del Chiaro, M, Conlon, K, Castillo, C, Friess, H, Fusai, G, Gianotti, L, Hackert, T, Halloran, C, Izbicki, J, Kalkum, E, Kelemen, D, Kenngott, H, Kretschmer, R, Landre, V, Lillemoe, K, Miao, Y, Marchegiani, G, Mihaljevic, A, Radenkovich, D, Salvia, R, Sandini, M, Serrablo, A, Shrikhande, S, Shukla, P, Siriwardena, A, Strobel, O, Uzunoglu, F, Vollmer, C, Weitz, J, Wolfgang, C, Zerbi, A, Bassi, C, Dervenis, C, Neoptolemos, J, Buchler, M, Diener, M, Probst P., Huttner F. J., Meydan O., Abu Hilal M., Adham M., Barreto S. G., Besselink M. G., Busch O. R., Bockhorn M., Del Chiaro M., Conlon K., Castillo C. F. -D., Friess H., Fusai G. K., Gianotti L., Hackert T., Halloran C., Izbicki J., Kalkum E., Kelemen D., Kenngott H. G., Kretschmer R., Landre V., Lillemoe K. D., Miao Y., Marchegiani G., Mihaljevic A., Radenkovich D., Salvia R., Sandini M., Serrablo A., Shrikhande S., Shukla P. J., Siriwardena A. K., Strobel O., Uzunoglu F. G., Vollmer C., Weitz J., Wolfgang C. L., Zerbi A., Bassi C., Dervenis C., Neoptolemos J., Buchler M. W., Diener M. K., Probst, P, Huttner, F, Meydan, O, Abu Hilal, M, Adham, M, Barreto, S, Besselink, M, Busch, O, Bockhorn, M, Del Chiaro, M, Conlon, K, Castillo, C, Friess, H, Fusai, G, Gianotti, L, Hackert, T, Halloran, C, Izbicki, J, Kalkum, E, Kelemen, D, Kenngott, H, Kretschmer, R, Landre, V, Lillemoe, K, Miao, Y, Marchegiani, G, Mihaljevic, A, Radenkovich, D, Salvia, R, Sandini, M, Serrablo, A, Shrikhande, S, Shukla, P, Siriwardena, A, Strobel, O, Uzunoglu, F, Vollmer, C, Weitz, J, Wolfgang, C, Zerbi, A, Bassi, C, Dervenis, C, Neoptolemos, J, Buchler, M, Diener, M, Probst P., Huttner F. J., Meydan O., Abu Hilal M., Adham M., Barreto S. G., Besselink M. G., Busch O. R., Bockhorn M., Del Chiaro M., Conlon K., Castillo C. F. -D., Friess H., Fusai G. K., Gianotti L., Hackert T., Halloran C., Izbicki J., Kalkum E., Kelemen D., Kenngott H. G., Kretschmer R., Landre V., Lillemoe K. D., Miao Y., Marchegiani G., Mihaljevic A., Radenkovich D., Salvia R., Sandini M., Serrablo A., Shrikhande S., Shukla P. J., Siriwardena A. K., Strobel O., Uzunoglu F. G., Vollmer C., Weitz J., Wolfgang C. L., Zerbi A., Bassi C., Dervenis C., Neoptolemos J., Buchler M. W., and Diener M. K.

Abstract

Background: Pancreatic surgery is associated with considerable morbidity and, consequently, offers a large and complex field for research. To prioritize relevant future scientific projects, it is of utmost importance to identify existing evidence and uncover research gaps. Thus, the aim of this project was to create a systematic and living Evidence Map of Pancreatic Surgery. Methods: PubMed, the Cochrane Central Register of Controlled Trials, and Web of Science were systematically searched for all randomized controlled trials and systematic reviews on pancreatic surgery. Outcomes from every existing randomized controlled trial were extracted, and trial quality was assessed. Systematic reviews were used to identify an absence of randomized controlled trials. Randomized controlled trials and systematic reviews on identical subjects were grouped according to research topics. A web-based evidence map modeled after a mind map was created to visualize existing evidence. Meta-analyses of specific outcomes of pancreatic surgery were performed for all research topics with more than 3 randomized controlled trials. For partial pancreatoduodenectomy and distal pancreatectomy, pooled benchmarks for outcomes were calculated with a 99% confidence interval. The evidence map undergoes regular updates. Results: Out of 30,860 articles reviewed, 328 randomized controlled trials on 35,600 patients and 332 systematic reviews were included and grouped into 76 research topics. Most randomized controlled trials were from Europe (46%) and most systematic reviews were from Asia (51%). A living meta-analysis of 21 out of 76 research topics (28%) was performed and included in the web-based evidence map. Evidence gaps were identified in 11 out of 76 research topics (14%). The benchmark for mortality was 2% (99% confidence interval: 1%–2%) for partial pancreatoduodenectomy and <1% (99% confidence interval: 0%–1%) for distal pancreatectomy. The benchmark for overall complications was 53% (99%co

Published
2021

45. Chronischer Alkoholkonsum steigert den hepatischen und pulmonalen Schaden bei akuter experimenteller Pankreatitis

Author

Schneider, L., Pietschmann, M., Hartwig, W., Hackert, T., Marcos, S. S., Longerich, T., Gebhard, M. -M., Büchler, M. sW., Werner, J., Buhr, H. J., editor, Hölscher, A., editor, Izbicki, J. R., editor, Jauch, K. W., editor, Post, S., editor, Allgayer, H., editor, Bartsch, D. K., editor, Fries, H., editor, Ghadimi, B. M., editor, Habermann, J. K., editor, Kalthoff, H., editor, Schackert, H. K., editor, Bruns, C. J., editor, Duda, D. N., editor, Fändrich, F., editor, Heberer, M., editor, Nüssler, A. K., editor, Stark, G. B., editor, Brückner, U. B., editor, Ertel, W., editor, Faist, E., editor, Heidecke, C. D., editor, Kalff, J. C., editor, Menger, M. D., editor, Schade, U. F., editor, Vollmar, B., editor, Bechstein, W. O., editor, Klar, E., editor, Klempnauer, J., editor, Minor, T., editor, Neuhaus, P., editor, Schmidt, J., editor, Langer, S., editor, Laschke, M. W., editor, Machens, H. G., editor, Steinau, H. U., editor, Südkamp, N., editor, Vogt, P., editor, Berger, D., editor, Klinge, U., editor, Schachtrupp, A., editor, Schilling, M. K., editor, Schumpelick, V., editor, Altendorf-Hofmann, A., editor, Bollschweiler, E., editor, Bruch, H. -P., editor, Lehnert, T., editor, Lorenz, W., editor, Neugebauer, E., editor, Ohmann, C., editor, Seiler, C. M., editor, Becker, H., editor, Betzler, M., editor, Bittner, R., editor, Broelsch, C., editor, Büchler, M. W., editor, Bumm, R., editor, Dralle, H., editor, Friess, H., editor, Frilling, A., editor, Germer, C. T., editor, Hopt, U., editor, Jonas, S., editor, Jost, J., editor, Markus, B., editor, Raab, H. R., editor, Reith, H. B., editor, Schlag, P. M., editor, Teichmann, W., editor, Uhl, W., editor, Wenisch, H., editor, and Zornig, C., editor

Published
2009
Full Text
View/download PDF

47. Robotic distal pancreatectomy, a novel standard of care? First benchmark values for surgical outcomes from 14 international expert centers

Author

Müller, P, primary, Breuer, E, additional, Tschuor, C, additional, Saint-Marc, O, additional, Keck, T, additional, Coratti, A, additional, De Oliveira, M, additional, Allen, P, additional, Giulianotti, P, additional, Oberkofler, C, additional, Nickel, F, additional, Groot Koerkamp, B, additional, Martinie, J, additional, Yeo, C, additional, Hackert, T, additional, Petrowsky, H, additional, He, J, additional, Boggi, U, additional, Borel-Rinkes, I H, additional, and Clavien, P-A, additional

Published
2022
Full Text
View/download PDF

48. Gadoliniumchlorid und Glycin verbessern den Pankreatitis assoziierten hepatischen Gewebeschäden und die pankreatische Mikrozirkulationsstörungen bei äthyltoxischer Pankreatitis der Ratte

Author

Schneider, L., Krych, R., Hartwig, W., Longerich, T., Hackert, T., Fritz, St., Gebhard, M. M., Büchler, M. W., Werner, J., Bruch, H. P., editor, Büchler, M. W., editor, Buhr, H. J., editor, Hohenberger, W., editor, Klar, E., editor, Kremer, B., editor, Post, S., editor, Schilling, M., editor, Schumpelick, V., editor, Siewert, J. R., editor, Thiede, A., editor, Becker, H., editor, Bittner, R., editor, Függer, R., editor, Köckerling, F., editor, Saeger, H. D., editor, Zornig, C., editor, Hölscher, A., editor, Izbicki, J. R., editor, Junginger, T., editor, Senninger, N., editor, Allgayer, H., editor, Broll, R., editor, Bruns, C. J., editor, Fries, H., editor, Kalthoff, H., editor, Schackert, H. K., editor, Ertel, W., editor, Faist, E., editor, Holzheimer, R. G., editor, Holzmann, B., editor, Schade, U. F., editor, Vollmar, B., editor, Brückner, U. B., editor, Heidecke, C. D., editor, Menger, M. D., editor, Neugebauer, E., editor, Spiegel, H. U., editor, Biemer, E., editor, Germann, G., editor, Haas, N., editor, Machens, H. G., editor, Stark, G. B., editor, Steinau, H. U., editor, Haverich, A., editor, Heberer, M., editor, Rogiers, X., editor, Jauch, K. W., editor, Roth, H., editor, von Schweinitz, D., editor, Waag, K. L., editor, Altendorf-Hofmann, A., editor, Celik, I., editor, Lehnert, T., editor, Lorenz, W., editor, Ohmann, C., editor, Bechstein, W. O., editor, Broelsch, C., editor, Hopt, U., editor, Klempnauer, J., editor, Neuhaus, P., editor, Fändrich, F., editor, Markus, B., editor, Minor, T., editor, Wonigeit, K., editor, Dralle, H., editor, Goretzki, P. E., editor, Rothmund, M., editor, Bühren, V., editor, Josten, C., editor, Muhr, G., editor, Nast-Kolb, D., editor, Stürmer, K. M., editor, Trentz, O., editor, Brunkwall, J., editor, Sandmann, W., editor, Schmitz-Rixen, T., editor, Storck, M., editor, Branscheid, D., editor, Dienemann, H., editor, Hirner, A., editor, Passlick, B., editor, Toomes, H., editor, Beyersdorf, F., editor, Hetzer, R., editor, Schäfers, H. J., editor, Zerkowski, H. R., editor, Becker, H. D., editor, Saeger, H. -D., editor, Jauch, K. -W., editor, and Bauer, H., editor

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results